SCHEMBL2998723

SCHEMBL2998723

O=C(NNC1CCCC1)c1ccncc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.68
ALDH1A1 P00352 2/20 0.60
GAA P10253 3/20 0.57
GFER P55789 1/20 0.57
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
PTGS2 P35354 1/20 0.53
TP53 P04637 1/20 0.51
HPGD P15428 2/20 0.49
LMNA P02545 1/20 0.49
CA1 P00915 1/20 0.49
CA9 Q16790 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
EPHX1 P07099 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MPO P05164 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
ADORA3 P0DMS8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2984435 0.98 L3MBTL1 (0.70) L3MBTL1ALDH1A1GAAGFERMAOA
SCHEMBL2998695 0.98 L3MBTL1 (0.70) L3MBTL1ALDH1A1GAAGFERMAOA
SCHEMBL8180075 0.84 NPC1 (0.60) L3MBTL1PTGS2CA1CA9MEN1
SCHEMBL27470376 0.83 ALDH1A1 (0.60) L3MBTL1ALDH1A1GAAMAOAMAOB
SCHEMBL6639389 0.82 RAB9A (0.61) L3MBTL1ALDH1A1GAAPTGS2HPGD
SCHEMBL11623816 0.81 L3MBTL1 (0.74) L3MBTL1ALDH1A1GAAGFERMAOA
SCHEMBL8387722 0.81 DEGS1 (0.53) L3MBTL1ALDH1A1GAAGFERHPGD
SCHEMBL2992964 0.77 ALDH1A1 (1.00) L3MBTL1ALDH1A1GAAMAOAMAOB
SCHEMBL29268969 0.76 NPC1 (0.55) GAAPTGS2HPGDCA1CA9
SCHEMBL30516201 0.75 METAP2 (0.52) GAATP53HPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB L3MBTL1 1229/4885ALDH1A1 302/4885GAA 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.